155 related articles for article (PubMed ID: 15375314)
1. Clinical studies of antisense oligonucleotides for cancer therapy.
Orr RM; Dorr FA
Methods Mol Med; 2005; 106():85-111. PubMed ID: 15375314
[No Abstract] [Full Text] [Related]
2. Antisense therapy in clinical oncology: preclinical and clinical experiences.
Tamm I
Methods Mol Med; 2005; 106():113-34. PubMed ID: 15375315
[No Abstract] [Full Text] [Related]
3. Antisense approaches for the treatment of cancer.
Monia BP; Holmlund J; Dorr FA
Cancer Invest; 2000; 18(7):635-50. PubMed ID: 11036471
[No Abstract] [Full Text] [Related]
4. Antisense therapy in oncology: new hope for an old idea?
Tamm I; Dörken B; Hartmann G
Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
[TBL] [Abstract][Full Text] [Related]
5. Antisense cancer therapy: the state of the science.
Kushner DM; Silverman RH
Curr Oncol Rep; 2000 Jan; 2(1):23-30. PubMed ID: 11122821
[TBL] [Abstract][Full Text] [Related]
6. Antisense approaches in drug discovery and development.
Rayburn E; Wang W; Zhang R; Wang H
Prog Drug Res; 2005; 63():227-74. PubMed ID: 16265883
[No Abstract] [Full Text] [Related]
7. Advancements of antisense oligonucleotides in treatment of breast cancer.
Yang SP; Song ST; Song HF
Acta Pharmacol Sin; 2003 Apr; 24(4):289-95. PubMed ID: 12676065
[TBL] [Abstract][Full Text] [Related]
8. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
[TBL] [Abstract][Full Text] [Related]
9. Selective gene therapy for proliferative disorders: sense and antisense.
Indolfi C; Chiariello M; Avvedimento EV
Nat Med; 1996 Jun; 2(6):634-5. PubMed ID: 8640548
[No Abstract] [Full Text] [Related]
10. Antisense oligonucleotide therapy for urologic tumors.
Kausch I; Böhle A
Curr Urol Rep; 2003 Feb; 4(1):60-9. PubMed ID: 12537941
[TBL] [Abstract][Full Text] [Related]
11. Antisense--time to shoot the messenger.
Kuss B; Cotter F
Ann Oncol; 1999 May; 10(5):495-503. PubMed ID: 10415997
[No Abstract] [Full Text] [Related]
12. Use of c-myb antisense oligonucleotides to increase the sensitivity of human colon cancer cells to cisplatin.
Funato T; Satou J; Kozawa K; Fujimaki S; Miura T; Kaku M
Oncol Rep; 2001; 8(4):807-10. PubMed ID: 11410788
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides.
Sypniewski D; Bednarek I; Gałka S; Loch T; Błaszczyk D; Sołtysik D
Acta Pol Pharm; 2013; 70(1):87-97. PubMed ID: 23610963
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotides as inhibitors of signal transduction: development from research tools to therapeutic agents.
Dean NM; McKay R; Miraglia L; Geiger T; Müller M; Fabbro D; Bennett CF
Biochem Soc Trans; 1996 Aug; 24(3):623-9. PubMed ID: 8878816
[No Abstract] [Full Text] [Related]
16. Ras/Raf signalling and emerging pharmacotherapeutic targets.
Kolch W
Expert Opin Pharmacother; 2002 Jun; 3(6):709-18. PubMed ID: 12036410
[TBL] [Abstract][Full Text] [Related]
17. Clinical studies of antisense therapy in cancer.
Yuen AR; Sikic BI
Front Biosci; 2000 Jun; 5():D588-93. PubMed ID: 10833467
[TBL] [Abstract][Full Text] [Related]
18. Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease.
Green DW; Roh H; Pippin J; Drebin JA
J Am Coll Surg; 2000 Jul; 191(1):93-105. PubMed ID: 10898188
[No Abstract] [Full Text] [Related]
19. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy.
Kim R; Emi M; Tanabe K; Toge T
Cancer; 2004 Dec; 101(11):2491-502. PubMed ID: 15503311
[TBL] [Abstract][Full Text] [Related]
20. Human Bcl-2 antisense therapy for lymphomas.
Cotter FE; Waters J; Cunningham D
Biochim Biophys Acta; 1999 Dec; 1489(1):97-106. PubMed ID: 10807000
[No Abstract] [Full Text] [Related]
[Next] [New Search]
